Committee Composition

= Chair

= Member

	Audit	Compensation	Nominating and Corporate Governance
James W. Young, Ph.D.
Executive Chairman Since May 2000, James W. Young, Ph.D. has been Executive Chairman of our board of directors. Dr. Young was the Chief Executive Officer of Sunesis from May 2000 until November 2003. In April 2006, Dr. Young joined 5AM Ventures, a venture capital firm, as a venture partner. Prior to joining Sunesis, Dr. Young served as Vice President for Research; Senior Vice President, Research and Development; and Group Vice President at ALZA Corporation from 1995 to 2000. From 1992 to 1995, Dr. Young served as Senior Vice President for Business Development and as President of the Pharmaceuticals Division of Affymax, N.V. From 1987 to 1992, he served as Senior Vice President for Business Development and as Senior Vice President and General Manager of the Pharmaceuticals Division at Sepracor Inc. Dr. Young holds a B.S. in Chemistry from Fordham University and a Ph.D. in Organic Chemistry from Cornell University.
Anthony B. Evnin, Ph.D.
Director Venrock Associates Anthony B. Evnin, Ph.D. has served as a member of our board of directors since 1998. Dr. Evnin has been with Venrock Associates, a venture capital firm, since 1974 and is currently a General Partner. He is currently a member of the Board of Directors of Coley Pharmaceutical Group, Inc., Icagen, Inc., Infinity Pharmaceuticals, Inc., Memory Pharmaceuticals Corp., Pharmos Corporation and Renovis, Inc., each a biopharmaceutical company. He holds an A.B. in Chemistry from Princeton University and a Ph.D. in Chemistry from Massachusetts Institute of Technology.
Daniel N. Swisher, Jr.
Chief Executive Officer and President Since December 2003, Daniel N. Swisher, Jr. has served as Chief Executive Officer and a member of the Sunesis Board of Directors, and as our President since August 2005. Mr. Swisher joined the company in 2001 and he served as Chief Business Officer and Chief Financial Officer until 2003. Prior to joining Sunesis, Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing for ALZA Corporation from 1992 to 2001. Mr. Swisher joined the board of the Okizu Foundation in 2007, an organization that provides support to families affected by childhood cancers. Mr. Swisher holds a B.A. in History from Yale University and an M.B.A. from the Stanford Graduate School of Business.
Stephen P.A. Fodor, Ph.D.
Director Affymetrix, Inc. Stephen P.A. Fodor, Ph.D. has served as a member of our board of directors since 2001. Dr. Fodor is founder, Chairman and Chief Executive Officer of Affymetrix, Inc., a biotechnology company. He is also cofounder of Perlegen Sciences, Inc., a biotechnology company, and has served as Chairman of Perlegen's Board of Directors since the company's inception. Dr. Fodor previously held various positions at the Affymax Research Institute from 1989 to 1992, where he led the development of the GeneChip Technology. Dr. Fodor holds an M.S. in Biochemistry from Washington State University and an M.A. and Ph.D. in Chemistry from Princeton University.
Matthew K. Fust
Director Jazz Pharmaceuticals, Inc. Matthew Fust has served as a member of our board of directors since 2005. Mr. Fust is the Chief Financial Officer of Jazz Pharmaceuticals, Inc., a pharmaceutical company. From May 2002 to May 2003, Mr. Fust was Chief Financial Officer at Perlegen Sciences, Inc., a biotechnology company. From June 1996 to January 2002, he was an executive with ALZA Corporation, first as Controller and then as Chief Financial Officer. Mr. Fust holds a B.A. in Accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.
Steven D. Goldby
Director Symyx Technologies, Inc. Steven Goldby has served as a member of our board of directors since 2001. Mr. Goldby has served as Chairman and Chief Executive Officer at Symyx Technologies, Inc., a material sciences company from 1998 to June 2007, when he became Executive Chairman. From 1982 to 1997, Mr. Goldby served as Chief Executive Officer of MDL Information Systems, Inc. From 1968 to 1973, Mr. Goldby held various management positions at ALZA Corporation, including President of ALZA Pharmaceuticals. In October 2007, Mr. Goldby joined Venrock Associates, a venture capital firm, as a Partner. Mr. Goldby holds a B.S. in chemistry from the University of North Carolina and a J.D. from Georgetown University Law School.
Jonathan S. Leff
Director Warburg Pincus LLC Mr. Leff has served as a member of our board of directors since 2000. He has served as a Partner of Warburg, Pincus & Co., which is the Managing Partner of Warburg Pincus LLC, and as a Managing Director and Member of Warburg Pincus LLC since January 2000. Mr. Leff served as a Vice President of Warburg Pincus LLC from January 1999 to December 1999 and as an Associate from July 1996 to December 1998. Mr. Leff serves on the Board of Directors of Allos Therapeutics, Inc., a biopharmaceutical company, Altus Pharmaceuticals Inc., a biopharmaceutical company, Intermune, Inc.,a biopharmaceutical company, Neurogen Corporation, a small molecule drug discovery and development company, and ZymoGenetics, Inc., a biotherapeutic company. Mr. Leff holds a B.A. from Harvard University and an M.B.A. from the Stanford Graduate School of Business.
Homer L. Pearce, Ph.D.
Director Eli Lilly & Company, retired Dr. Pearce has served as a member of our board of directors since June 2006. Dr. Pearce served in various capacities at Eli Lilly & Company since joining the company in 1979, including Vice President, Cancer Research and Clinical Investigation from 1994 to 2002 and Fellow, Cancer Research, Lilly Research Laboratories from 2002 to March 2006. Since August 2006, Dr. Pearce has served as a consultant to our company. He is a member of the American Association for Cancer Research, the American Chemical Society and the American Association for the Advancement of Science. He received a B.S. from Texas A&M University and his Ph.D. from Harvard University.
David C. Stump, M.D.
Director Human Genome Sciences, Inc. Dr. Stump has served as a member of our board of directors since June 2006. He is Executive Vice President, Research and Development at Human Genome Sciences, Inc., and has served at the company since November 1999. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., from 1989 to 1999, most recently as Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Since September 2006, Dr. Stump has served as a consultant to our company. He earned an A.B. from Earlham College and an M.D. at Indiana University, followed by residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa.